 Immutep Limited ASX: IMM; NASDAQ: IMMP Immutep or the Company, is pleased to report that it has been informed its Chinese partner, EOC Pharma, has completed patient recruitment for the ongoing EOC202A1101 study being conducted in China. EOC Pharma is an oncology focused specialty pharmaceutical company headquartered in Shanghai, China, and is the exclusive licensee of eftilagimod alpha efti or IMP321 from Immutep for the Chinese market. 